Skip to content

Investigation the effect of Falcaria vulgaris on vitiligo

Investigation the effect of Falcaria vulgaris on vitiligo

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160627028664N3
Enrollment
62
Registered
2020-10-05
Start date
2020-10-22
Completion date
Unknown
Last updated
2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo. Vitiligo

Interventions

Intervention 1: Intervention group: In this study, first the seeds of Atrilal plant are prepared and after identifying and confirming the scientific name in the pharmacognosy group of Hamadan School o

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Clinical diagnosis of vitiligo recently or in case of previous diagnosis of non-drug use from one month ago Normal blood, liver, kidney, anti-nuclear antibody (ANA) tests and eye examination

Exclusion criteria

Exclusion criteria: Use of effective concomitant treatment in vitiligo Pregnancy Personal or family history of light-sensitive Suffering from light-sensitive diseases such as lupus and porphyria Use of light-sensitizing drugs such as retinoids and cotrimoxazole

Design outcomes

Primary

MeasureTime frame
Size of skin lesions. Timepoint: At the beginning of the study, after 20 days, after a month, after two months. Method of measurement: Based on standard grading VASI and VIDA.;Color of skin lesions. Timepoint: At the beginning of the study, after 20 days, after a month, after two months. Method of measurement: Based on standard grading VASI and VIDA.;Follicular pigmentation. Timepoint: At the beginning of the study, after 20 days, after a month, after two months. Method of measurement: Based on standard grading VASI and VIDA.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzam Meyari

Hamedan University of Medical Sciences

d_a_meyari@yahoo.com+98 81 3838 0238

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026